Brandon M. White

Robert L. Florence

Micheal L. Binns

Karen L. Carroll

Stamatios Stamoulis

Melanie B. Dubis

Sharad K. Bijanki

Christopher M. Thomas

Catherine Lawson

Katherine Graham

Amy K. Wigmore

Andrew J. Danford

Kevin M. Yurkerwich

Tracey C. Allen

Brian E. Farnan

Gregory H. Lantier

Jeffrey T. Hantson

Timothy A. Cook

Heather M. Petruzzi

ANDA filing triggers Pfizer/BMS clash with Mylan over generic Eliquis®, disputing patents on its `apixaban` compound and `D90 particle size` formulation.

Prosecution History analysis

Examiner Search analysis

Invalidity Framework analysis

Name	Ratings
Bristol-Myers Squibb Co	L4 A
Pfizer Inc	L5 A

Name	Ratings
Wilmer Cutler Pickering Hale Dorr LLP	L5 A
Gregory H. Lantier	L3 A
Amy K. Wigmore	L3 E
Timothy A. Cook	L2 A
Tracey C. Allen	L2 B
Andrew J. Danford	L1 D
Heather M. Petruzzi	L1 E
Kevin M. Yurkerwich	-- -- --
Jeffrey T. Hantson	-- -- --
Farnan LLPLocal	L4 E
Brian E. Farnan	L5 E

Name	Ratings
Perkins Coie LLP	L5 A
Brandon M. White	L3 B
Stamoulis & WeinblattLocal	L3 E
Stamatios Stamoulis	L4 E
Parker Poe Adams & Bernstein LLP	L2 C
Karen L. Carroll	L3 A
Robert L. Florence	L3 C
Micheal L. Binns	L3 D
Christopher M. Thomas	L2 A
Melanie B. Dubis	L2 B
Catherine Lawson	L1 B
Sharad K. Bijanki	-- -- --
Katherine Graham	-- -- --

1:17-cv-00379

Bristol Myers Squibb Co v. Mylan Pharma Inc